Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
National Institutes of Health (NIH)
Estimated funding amount: $150,000 per award
Anticipated number of awards: 3
Project period: Up to 2 years, not to exceed the remaining years on the parent grant
Encourage revision applications from currently funded NCI P50 specialized centers
Expand upon original research questions or accelerate progress by incorporating new technologies developed through the NCI IMAT program
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Research institutions and cancer research communities
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local governments, state governments, and federal agencies.
Specific eligible organizations include public/state controlled institutions of higher education, private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses, and various levels of government.
Eligible organizations can be based in the U.S. or be foreign organizations.
Non-domestic components of U.S. organizations are also eligible.
Projects must propose to incorporate new technical approaches or devices developed through the NCI IMAT program.
Applications should aim to expand upon original research questions or accelerate progress for the parent study.
Direct costs are limited to $150,000 per year.
No cost sharing is required.
Application due date: October 3, 2025.
Open date for submissions: March 4, 2025.
Applicants must be currently funded NCI P50 awardees.
Applications cannot request funds beyond the end date of the parent award.
Applications must follow the Multi-Project Instructions in the How to Apply - Application Guide.
A letter of intent is encouraged but not required.
Applications will be evaluated based on scientific and technical merit through the NIH peer review system.
Applications will undergo a scientific peer review and a second level of review by the appropriate national Advisory Council or Board.
Scientific and technical merit of the proposed project will be a key factor in funding decisions.
Applications must incorporate technology platforms developed through the NCI IMAT program.
Applications proposing to incorporate commercially available technologies or technologies not developed through the NCI IMAT program will be considered non-responsive.
Demonstrating the potential impact of the proposed technology on cancer research.
Submitting applications that overlap significantly with other applications under review.
Engage with the Scientific/Research Contact for assistance in finding suitable technology platforms.